|
Session 91
Poster Abstracts
Clinical Trials of RTIs
Tuesday, 1 - 4 pm
Poster Hall |
503
 |
Early Virologic Non-response to Once Daily Combination of Lamivudine, Tenofovir, and Nevirapine in ART-naive HIV-infected Patients: Preliminary Results of the DAUFIN Study
David Rey*1, M P Schmitt1, G Hoizey2, P Meyer1, P Chavanet3, C Allavena4, M Diemer5, T May6, B Hoen7, and J M Lang1
1Univ Hosp, Strasbourg, France; 2Univ Hosp, Reims, France; 3Univ Hosp, Dijon, France; 4Univ Hosp, Nantes, France; 5Lariboisiere Univ Hosp, Paris, France; 6Univ Hosp, Nancy, France; and 7Univ Hosp, Besançon, France |
504
|
Didanosine, Lamivudine, and Efavirenz vs Zidovudine, Lamivudine, and Efavirenz, for Initial Treatment of HIV Infection: Planned 24-Week Analysis of a Prospective Randomized Non-inferiority Clinical Trial, GESIDA 39/03
Juan Berenguer*1, E Ribera2, P Domingo3, R Palacios4, P Miralles1, M Ribas5, J González6, V Asensi7, J Gimeno8, A Terrón9, and GESIDA 3903 Team
1Hosp Gregorio Maranon, Madrid, Spain; 2Hosp Vall d'Hebron, Barcelona, Spain; 3Hosp Sant Pau, Barcelona, Spain; 4Hosp Virgen de la Victoria, Malaga, Spain; 5Hosp Son Dureta, Palma de Mallorca, Spain; 6Hosp La Paz, Madrid, Spain; 7Hosp Central Asturias, Oviedo, Spain; 8Hosp del Mar, Barcelona, Spain; and 9Hosp de Jerez, Spain |
| 505 |
Efficacy and Safety of Tenofovir-containing vs non-Tenofovir-containing Regimens in Black ART-naive Patients
Joel Gallant*1, A Pozniak2, S Staszewski3, E DeJesus4, S S Chen5, J Enejosa5, and A Cheng5
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Chelsea and Westminster Hosp, London, UK; 3JW Goethe Univ, Frankfurt, Germany; 4Orlando Immunology Ctr, FL, US; and 5Gilead Sci, Foster City, CA, US |
| 506 |
Superior Virological Suppression with Nevirapine, Zidovudine, and Lamivudine vs Abacavir, Zidovudine, and Lamivudine without Evidence of Clinical Benefit to 48 Weeks: A Randomized Comparison in Patients with Low CD4 Counts in Africa
Sarah Walker*1, C Kityo2, P Kaleebu3, F Ssali2, F Lyagoba3, A Reid4, D Gibb1, C Gilks5, P Mugyenyi2, P Munderi3, and the DART Trial Team
1Med Res Council Clin Trials Unit, London, UK; 2Joint Clin Res Ctr, Kampala, Uganda; 3Med Res Council/Uganda Virus Res Inst, Entebbe; 4Univ of Zimbabwe, Harare; and 5Imperial Coll, London, UK |
507
|
HAART Outcomes among HIV-1C-infected Adults in Botswana: Interim Results from a Randomized Clinical Trial
Hermann Bussmann*1,2, Hermann Bussmann*1,2, C Wester1,2, C Wester1,2, A Thomas2, V DeGruttola2, O Okezie1, S Moyo1, M Mine1, J Makhema1, M Essex1,2, M Essex1,2, R Marlink1,2, and R Marlink1,2
1Botswana-Harvard Partnership and 2Harvard Sch of Publ Hlth, Boston, MA, US |
508
|
Audio Computer-assisted Self-Interview Improves HIV-1 Viral Suppression in African American Women: Results from a Randomized, Controlled Study
Beulah Sabundayo*, J Keruly, G Lucas, and R Moore
Johns Hopkins Univ Sch of Med, Baltimore, MD, US |
|
